Physician profile
Michael Patton
NPI 1669859153
$2,493.27
in general payments reported to CMS, 2019-2025
35 companies · $546 in 2025
The $546 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $106 · 2021: $314 · 2022: $213 · 2023: $603 · 2024: $303 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.12 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $427.24 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $200.61 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $145.90 | 2021 | |
| Agiliti Surgical, INC. | $139.39 | 2023 | Soltive |
| Urogen Pharma, INC. | $133.06 | 2022-2025 | Jelmyto |
| Myovant Sciences INC. | $126.58 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $116.82 | 2020-2025 | Provenge |
| Abbvie INC. | $112.92 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.51 | 2020-2025 | |
| Pfizer INC. | $67.72 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $66.52 | 2024-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $61.78 | 2022-2023 | Lynparza, Welireg, Keytruda |
| Neotract INC. | $61.09 | 2020 | |
| Myriad Genetic Laboratories, INC. | $57.16 | 2024 | Prolaris |
| Amgen INC. | $56.38 | 2021-2023 | Xgeva, Prolia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $55.62 | 2023-2024 | Speedicath |
| Tolmar, INC. | $49.31 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $48.33 | 2023-2025 | Imfinzi, Lynparza |
| Calyxo, INC. | $44.06 | 2023 | Cvac Aspiration System |
| Teleflex LLC | $37.92 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $35.64 | 2023 | Xiaflex, Aveed |
| Immunitybio, INC. | $34.95 | 2025 | |
| Medtronic, INC. | $34.74 | 2025 | Interstim |
| Olympus America INC. | $32.47 | 2023-2025 | Itind System |
| Allergan, INC. | $31.75 | 2021 | |
| Novo Nordisk INC | $29.82 | 2025 | Rivfloza |
| Progenics Pharmaceuticals, INC. | $24.44 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $23.58 | 2023 | Seglentis |
| Tolmar Pharmaceuticals, INC. | $23.25 | 2022 | |
| Palette Life Sciences, INC. | $20.58 | 2023 | |
| Organon LLC | $20.20 | 2025 | |
| Accord Healthcare, INC. | $18.26 | 2023 | |
| Janssen Biotech, INC. | $18.09 | 2022 | |
| Cardinal Health 414 LLC | $17.14 | 2023 | |
| Bioprotect Medical, INC. | $16.44 | 2025 | Bioprotect Balloon Implant System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.